The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders—a double-blind, randomized, placebo-controlled proof-of-concept study

Peer Review reports

Original Submission
19 Jan 2024	Submitted	Original manuscript
29 Mar 2024	Reviewed	Reviewer Report - Kirsty Loudon
9 Apr 2024	Author responded	Author comments - Lisa-Marie Brunner
Resubmission - Version 2
9 Apr 2024	Submitted	Manuscript version 2
Publishing
16 Apr 2024	Editorially accepted
22 Apr 2024	Article published	10.1186/s13063-024-08120-x

Back to article page